497 related articles for article (PubMed ID: 17289889)
21. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma.
Iwata N; Yamamoto H; Sasaki S; Itoh F; Suzuki H; Kikuchi T; Kaneto H; Iku S; Ozeki I; Karino Y; Satoh T; Toyota J; Satoh M; Endo T; Imai K
Oncogene; 2000 Nov; 19(46):5298-302. PubMed ID: 11077447
[TBL] [Abstract][Full Text] [Related]
22. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation.
Oh BK; Kim H; Park HJ; Shim YH; Choi J; Park C; Park YN
Int J Mol Med; 2007 Jul; 20(1):65-73. PubMed ID: 17549390
[TBL] [Abstract][Full Text] [Related]
23. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
24. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas.
Oue N; Motoshita J; Yokozaki H; Hayashi K; Tahara E; Taniyama K; Matsusaki K; Yasui W
J Pathol; 2002 Sep; 198(1):55-9. PubMed ID: 12210063
[TBL] [Abstract][Full Text] [Related]
25. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
[TBL] [Abstract][Full Text] [Related]
26. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients.
Wong IH; Lo YM; Yeo W; Lau WY; Johnson PJ
Clin Cancer Res; 2000 Sep; 6(9):3516-21. PubMed ID: 10999738
[TBL] [Abstract][Full Text] [Related]
27. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients.
Wang J; Qin Y; Li B; Sun Z; Yang B
Clin Biochem; 2006 Apr; 39(4):344-8. PubMed ID: 16527261
[TBL] [Abstract][Full Text] [Related]
28. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ
Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049
[TBL] [Abstract][Full Text] [Related]
29. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma.
Lee HS; Kim BH; Cho NY; Yoo EJ; Choi M; Shin SH; Jang JJ; Suh KS; Kim YS; Kang GH
Clin Cancer Res; 2009 Feb; 15(3):812-20. PubMed ID: 19188151
[TBL] [Abstract][Full Text] [Related]
30. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis.
Lee S; Lee HJ; Kim JH; Lee HS; Jang JJ; Kang GH
Am J Pathol; 2003 Oct; 163(4):1371-8. PubMed ID: 14507645
[TBL] [Abstract][Full Text] [Related]
31. Review of genetic and epigenetic alterations in hepatocarcinogenesis.
Herath NI; Leggett BA; MacDonald GA
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):15-21. PubMed ID: 16706806
[TBL] [Abstract][Full Text] [Related]
32. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter.
Sohn BH; Park IY; Lee JJ; Yang SJ; Jang YJ; Park KC; Kim DJ; Lee DC; Sohn HA; Kim TW; Yoo HS; Choi JY; Bae YS; Yeom YI
Gastroenterology; 2010 May; 138(5):1898-908. PubMed ID: 20038433
[TBL] [Abstract][Full Text] [Related]
33. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis.
Saito Y; Kanai Y; Sakamoto M; Saito H; Ishii H; Hirohashi S
Hepatology; 2001 Mar; 33(3):561-8. PubMed ID: 11230735
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search.
Moribe T; Iizuka N; Miura T; Stark M; Tamatsukuri S; Ishitsuka H; Hamamoto Y; Sakamoto K; Tamesa T; Oka M
Int J Oncol; 2008 Nov; 33(5):949-58. PubMed ID: 18949357
[TBL] [Abstract][Full Text] [Related]
35. CpG island methylation in carcinoid and pancreatic endocrine tumors.
Chan AO; Kim SG; Bedeir A; Issa JP; Hamilton SR; Rashid A
Oncogene; 2003 Feb; 22(6):924-34. PubMed ID: 12584572
[TBL] [Abstract][Full Text] [Related]
36. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population.
Tang SH; Yang DH; Huang W; Zhou HK; Lu XH; Ye G
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4171-7. PubMed ID: 16857788
[TBL] [Abstract][Full Text] [Related]
37. Promoter methylation status of multiple genes in uveal melanoma.
Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
[TBL] [Abstract][Full Text] [Related]
38. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan.
Hsu LS; Lee HC; Chau GY; Yin PH; Chi CW; Lui WY
Oncol Rep; 2006 Feb; 15(2):507-11. PubMed ID: 16391877
[TBL] [Abstract][Full Text] [Related]
39. Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior.
Geli J; Kiss N; Karimi M; Lee JJ; Bäckdahl M; Ekström TJ; Larsson C
Clin Cancer Res; 2008 May; 14(9):2551-9. PubMed ID: 18451216
[TBL] [Abstract][Full Text] [Related]
40. The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma.
Tsunedomi R; Ogawa Y; Iizuka N; Sakamoto K; Tamesa T; Moribe T; Oka M
Int J Oncol; 2010 Jan; 36(1):205-12. PubMed ID: 19956849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
